Leerink Partnrs Issues Optimistic Outlook for RXRX Earnings

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) – Research analysts at Leerink Partnrs raised their Q2 2025 earnings per share estimates for Recursion Pharmaceuticals in a note issued to investors on Tuesday, June 10th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($0.27) for the quarter, up from their prior estimate of ($0.34). The consensus estimate for Recursion Pharmaceuticals’ current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for Recursion Pharmaceuticals’ Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($1.29) EPS, FY2026 earnings at ($0.81) EPS and FY2027 earnings at ($0.30) EPS.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.06). The business had revenue of $14.75 million for the quarter, compared to the consensus estimate of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals’s revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.39) earnings per share.

Several other equities analysts have also recently weighed in on the company. Morgan Stanley decreased their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating for the company in a report on Thursday, April 10th. Needham & Company LLC decreased their price target on Recursion Pharmaceuticals from $11.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, May 6th. Cowen restated a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Finally, Leerink Partners decreased their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Friday, February 28th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $7.60.

Recursion Pharmaceuticals Stock Down 4.8%

Recursion Pharmaceuticals stock opened at $4.92 on Friday. The company has a market cap of $2.00 billion, a P/E ratio of -3.22 and a beta of 0.84. Recursion Pharmaceuticals has a 1-year low of $3.79 and a 1-year high of $12.36. The company has a fifty day simple moving average of $4.89 and a 200 day simple moving average of $6.32. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in RXRX. Private Trust Co. NA bought a new position in Recursion Pharmaceuticals during the fourth quarter worth $27,000. AlphaQuest LLC bought a new stake in shares of Recursion Pharmaceuticals during the 1st quarter worth about $36,000. GAMMA Investing LLC boosted its holdings in shares of Recursion Pharmaceuticals by 39.0% during the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after buying an additional 2,026 shares during the period. Farther Finance Advisors LLC boosted its holdings in shares of Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock worth $52,000 after buying an additional 1,353 shares during the period. Finally, NewEdge Advisors LLC boosted its holdings in shares of Recursion Pharmaceuticals by 43.7% during the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company’s stock worth $53,000 after buying an additional 2,387 shares during the period. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.